Verona Pharma plc (VRNA) Analysts See $-0.49 EPS

October 13, 2018 - By Dolores Ford

Analysts expect Verona Pharma plc (NASDAQ:VRNA) to report $-0.49 EPS on November, 6.They anticipate $0.42 EPS change or 46.15 % from last quarter’s $-0.91 EPS. After having $0.06 EPS previously, Verona Pharma plc’s analysts see -916.67 % EPS growth. The stock increased 1.41% or $0.1696 during the last trading session, reaching $12.1696. About 886 shares traded. Verona Pharma plc (NASDAQ:VRNA) has risen 6.30% since October 14, 2017 and is uptrending. It has underperformed by 9.32% the S&P500.

Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company has market cap of $158.60 million. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and IIa clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease and cystic fibrosis. It currently has negative earnings.

More important recent Verona Pharma plc (NASDAQ:VRNA) news were published by: Nasdaq.com which released: “Verona Pharma to Host Investor & Analyst R&D Forum on October 12, 2018” on September 27, 2018, also Seekingalpha.com published article titled: “Key events next week – healthcare”, Globenewswire.com published: “Issue of Shares & PDMR Announcement” on September 20, 2018. More interesting news about Verona Pharma plc (NASDAQ:VRNA) was released by: Benzinga.com and their article: “The Week Ahead In Biotech (Sept. 16-22): Conferences, PDUFA Dates, Clinical Trial Results And IPOs” with publication date: September 16, 2018.

Verona Pharma plc (NASDAQ:VRNA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>